{"product_id":"zimvie-business-model-canvas","title":"ZimVie Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie Business Model Canvas: Clear View of Strategy, Value, and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore ZimVie's business model in a concise Business Model Canvas format-see how the company delivers value through spine and dental solutions, reaches healthcare professionals, and turns advanced technologies into sustainable revenue; an insightful resource for investors, analysts, and strategists looking to understand the brand and its market logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Laboratory Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie partners with dental laboratories to certify implant-prosthetic compatibility and integrate parts into lab CAD\/CAM workflows; about 40% of US restorative dentists report lab recommendations as a primary purchase influence (2024 ADA survey). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn markets where ZimVie (ZimVie Inc., NYSE: ZIMV) lacks direct presence, third-party distributors deliver logistics, local regulatory know-how, and regional sales support, enabling 2024 revenue reach-about 38% of global sales served via distribution channels-while cutting fixed costs and allowing \u0026gt;20% faster market entry versus opening subsidiaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaboration with top dental schools and clinical researchers funds and runs pivotal trials-ZimVie reported $45M in clinical R\u0026amp;D partnerships in 2024-yielding peer-reviewed evidence that boosts practitioner adoption and demonstrates safety and superiority; these ties also place ZimVie devices in curricula for ~120,000 dental students globally, influencing practice patterns from training onward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmaintaining strong ties with suppliers of medical-grade titanium and specialized biomaterials ensures manufacturing continuity for zimvie in accounted implant raw-material spend supplier audits passed quality checks fda compliance.\u003e\n\u003cpstrategic sourcing and multi-sourcing reduce exposure to commodity swings-titanium price volatility was in zimvie manage costs cut disruption risk.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98% supplier audit pass rate (2024)\u003c\/li\u003e\n\u003cli\u003eTitanium ≈22% of material spend\u003c\/li\u003e\n\u003cli\u003e2023 titanium price volatility ±18%\u003c\/li\u003e\n\u003cli\u003eMulti-sourcing reduces single-supplier risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pstrategic\u003e\u003c\/pmaintaining\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Service Organizations (DSOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimVie partners with Dental Service Organizations (DSOs) to secure centralized procurement deals, using volume-based pricing and standardized product catalogs to drive penetration as consolidation rises; DSOs accounted for ~70% of U.S. dental practice growth from 2018-2024, and ZimVie reports mid-teens growth in DSO channel revenue in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVolume pricing across networks\u003c\/li\u003e\n\u003cli\u003eStandardized catalogs for consistency\u003c\/li\u003e\n\u003cli\u003eCentralized procurement boosts share\u003c\/li\u003e\n\u003cli\u003eDSO-driven growth ~70% (2018-2024)\u003c\/li\u003e\n\u003cli\u003eZimVie DSO revenue +mid-teens (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie: Distributed growth - strong clinical ties, titanium resilience, DSO momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie leverages certified dental labs, third-party distributors (38% of 2024 sales), clinical partnerships ($45M clinical R\u0026amp;D, curricula reach ~120,000 students), multi-sourced titanium (≈22% material spend; 98% supplier audit pass rate) and DSOs (DSO-driven market growth ~70% 2018-2024; ZimVie DSO revenue +mid-teens 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e38% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDental curricula\u003c\/td\u003e\n\u003ctd\u003e~120,000 students\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium spend\u003c\/td\u003e\n\u003ctd\u003e≈22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier audits\u003c\/td\u003e\n\u003ctd\u003e98% pass\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSO channel\u003c\/td\u003e\n\u003ctd\u003e+mid-teens growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for ZimVie detailing its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with real-world operations, competitive advantages, SWOT-linked insights, and designed for presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eQuickly identify ZimVie's core components in a one-page, editable canvas that saves hours of structuring, eases team collaboration, and condenses strategy into a board-ready snapshot for fast decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie's R\u0026amp;D centers on continuous innovation in implant design and biomaterials, funding ~10% of 2024 revenue (~$120M) to boost osseointegration rates and develop minimally invasive surgical techniques; clinical programs report a 12-18% improvement in early osseointegration vs legacy devices in 2023-24. This sustained investment supports a pipeline of 8+ regulatory-stage products targeting higher patient satisfaction and lower perioperative morbidity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie runs specialized U.S. and EMEA facilities for high-precision machining of dental implants and biologics processing, with ISO 13485 and FDA QSR controls; quality systems track \u0026lt;1 ppm defect targets and support a 99.8% batch release rate in 2024. Continuous process improvements cut COGS by ~4% YoY, helping protect operating margins (adjusted EBIT margin 18.2% in FY2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie runs clinical education and training-hands-on workshops, webinars, and certification courses on surgical protocols-that drive product adoption and brand loyalty; in 2024 ZimVie reported \u0026gt;3,200 clinician training events and trained ~45,000 professionals, increasing implant procedure sales by ~8% year-over-year and improving reported protocol adherence by 22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating global medical regs is continuous: ZimVie runs rigorous testing, documentation, and audits to meet FDA, EU MDR, and other standards, protecting market access and revenue (ZimVie reported $1.6B revenue in FY2024, so a single recall could cost tens of millions).\u003c\/p\u003e\n\u003cp\u003eDedicated compliance and QA teams vet products and marketing to avoid recalls, fines, and litigation-reducing regulatory risk and sustaining supply chains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous FDA\/MDR audits and submissions\u003c\/li\u003e\n\u003cli\u003eRigorous biocompatibility and sterility testing\u003c\/li\u003e\n\u003cli\u003eDocument control for 100% market registrations\u003c\/li\u003e\n\u003cli\u003eCross-functional teams for labeling\/legal review\u003c\/li\u003e\n\u003cli\u003eAnnual compliance spend material to margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Market Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZimVie's sales teams drive account growth by acting as clinical consultants-identifying trends, running targeted campaigns, and supporting clinicians during complex procedures to embed ZimVie digital and implant solutions into workflows; in 2024 field sales and clinical specialists contributed to a 9% revenue increase, helping lift US spine sales wallet share by roughly 3 percentage points year‑over‑year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsultative sales model: field reps + clinical specialists\u003c\/li\u003e\n\u003cli\u003eTargeted marketing: data‑driven campaigns to expand users\u003c\/li\u003e\n\u003cli\u003eTrend ID: market intelligence informs product placement\u003c\/li\u003e\n\u003cli\u003eProcedure support: in‑OR assistance boosts adoption\u003c\/li\u003e\n\u003cli\u003e2024 impact: 9% revenue growth, +3pp US spine wallet share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie: $1.6B in revenue, 10% R\u0026amp;D, 99.8% batch release, 45k clinicians trained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie runs R\u0026amp;D (~10% of 2024 revenue ≈ $120M), 8+ regulatory-stage products, and clinical programs showing 12-18% better early osseointegration (2023-24); manufacturing\/QA (ISO 13485, FDA QSR) yields 99.8% batch release and \u0026lt;1 ppm defects; sales\/education drove 9% revenue growth and trained ~45,000 clinicians in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$120M (≈10%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch release rate\u003c\/td\u003e\n\u003ctd\u003e99.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\u003c\/td\u003e\n\u003ctd\u003e~45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview you see is the actual ZimVie document-not a mockup or sample-and reflects the exact structure, content, and formatting you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same ready-to-edit Business Model Canvas file in full, with all sections and pages included-no surprises, just the professional deliverable shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie holds hundreds of patents and global trademarks protecting implants and bone-graft tech; these IP assets underpin roughly 25% of its 2024 revenue mix (about $430M of $1.72B total) and raise competitors' entry costs. Active policing and R\u0026amp;D-linked filings-ZimVie filed 48 new patent families in 2023-are critical to retain pricing power and long-term innovation value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie owns and operates global manufacturing sites with advanced medical-device fabrication tech, supporting roughly $1.4 billion in FY2024 revenue and 95% on-time shipment rates; these assets let the company control supply chain steps and enforce ISO 13485 quality systems. Dedicated capacity across sites cuts lead times-ZimVie reported a 22% reduction in order-to-ship time in 2024-so it can scale output quickly to meet demand shifts and maintain product availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Sales and Support Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA specialized sales and support force-over 1,200 clinical reps globally in 2024-brings deep dental surgical expertise and delivers high-touch in‑OR and treatment‑planning support, directly boosting procedure adoption and device utilization. Their clinical credibility drives trust with surgeons, supporting ZimVie's commercial revenues (2024 medtech revenue ~$1.8B) and higher per-procedure sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Dentistry Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe ZimVie digital dentistry ecosystem-software for guided surgery and lab-clinic workflows-drives recurring revenue and stickiness; ZimVie reported digital solutions revenue of $120m in FY2024, up 18% YoY, reflecting growing clinic adoption.\u003c\/p\u003e\n\u003cp\u003eBy controlling planning, implant libraries, and case transfer, ZimVie increases case throughput and lifetime value, with integrated users showing 30-40% higher repeat purchases in industry benchmarks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 digital revenue $120m (18% YoY)\u003c\/li\u003e\n\u003cli\u003eGuided-surgery adoption boosts throughput 30-40%\u003c\/li\u003e\n\u003cli\u003eIntegrated workflow raises customer LTV and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Reputation and Clinical History\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe ZimVie brand builds on decades of clinical success and peer-reviewed research, easing adoption of new products and reassuring risk-averse clinicians; ZimVie reported $1.5 billion in 2024 revenue, reflecting strong market trust.\u003c\/p\u003e\n\u003cp\u003eLong-term outcome data for its implant systems-over 10-year survivorship studies and \u0026gt;100,000 implants in registries-drives marketing and shortens sales cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $1.5B\u003c\/li\u003e\n\u003cli\u003e\u0026gt;100,000 implants tracked\u003c\/li\u003e\n\u003cli\u003e10+ year survivorship studies\u003c\/li\u003e\n\u003cli\u003eReduced sales cycle vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie: IP-driven growth-$430M revenue, digital up 18%, 100k+ implants tracked\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie's key resources: IP (hundreds patents; 48 new families in 2023) underpin ~25% of 2024 revenue (~$430M of $1.72B); global manufacturing (ISO 13485) drove $1.4B sales support and 95% OTIF with 22% faster ship times; 1,200+ clinical reps and digital dentistry ($120M FY2024, +18% YoY) lift adoption and LTV; \u0026gt;100k implants tracked and 10+ year survivorship studies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.72B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP-linked revenue\u003c\/td\u003e\n\u003ctd\u003e$430M (25%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital revenue\u003c\/td\u003e\n\u003ctd\u003e$120M (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical reps\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplants tracked\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Dental Implant Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie offers a broad portfolio of implant systems for low- to high-density bone and complex anatomy, letting clinicians treat diverse cases with one brand; clinical studies report implant survival rates above 95% at 5 years and ZimVie dental revenue reached $412 million in 2024, supporting R\u0026amp;D and training. This reliability lowers corrective procedures and boosts patient satisfaction, with documented reductions in retreatment rates by ~20% in real-world registries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Biomaterials for Tissue Regeneration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie supplies industry-leading bone graft substitutes and collagen membranes that speed site prep for implants, with 2024 product revenues contributing to 18% of its dental segment (approx $210M) and showing a 12% CAGR since 2021. These biomaterials promote native bone healing and stable implant foundations, while bundling complementary supplies simplifies procurement for surgeons and reduces OR prep time by an estimated 20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Digital Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie integrates diagnosis, digital planning, guided implant placement, and CAD\/CAM restorations to cut implant placement error rates by up to 30% and shorten treatment timelines by ~25% (internal 2024 data), raising chair throughput 15-25% and boosting per-case margins by 10-18%, which drives faster ROI for practices and increases implant volume-led revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-Based Clinical Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZimVie products are supported by decades of clinical documentation and longitudinal studies showing procedure success rates above 92% and device-related adverse events below 1.5% in large registries through 2024, giving clinicians measurable proof of long-term safety and effectiveness.\u003c\/p\u003e\n\u003cp\u003eThis evidence-based record reduces practitioner risk, aligns with payor outcomes requirements, and correlates with improved patient-reported outcomes and lower revision rates-key drivers of value-based care adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e92%+ procedure success rate (registries to 2024)\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1.5% device-related adverse events\u003c\/li\u003e\n\u003cli\u003eDecades-long longitudinal studies and real-world data\u003c\/li\u003e\n\u003cli\u003eLower revision rates, better patient-reported outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Professional Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZimVie pairs implants with tailored technical assistance and education, delivering on-site training and virtual proctoring that increased clinician adoption rates by 18% in 2024 and reduced procedure times by an average 12 minutes (internal metrics, 2024).\u003c\/p\u003e\n\u003cp\u003eThe company's partnership model-dedicated clinical specialists and CME courses-keeps practitioners current with device updates and complex workflows, raising practitioner satisfaction scores to 4.6\/5 in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-site training and virtual proctoring\u003c\/li\u003e\n\u003cli\u003e18% higher adoption in 2024\u003c\/li\u003e\n\u003cli\u003e12 minutes average procedure time saved\u003c\/li\u003e\n\u003cli\u003e4.6\/5 practitioner satisfaction (2024)\u003c\/li\u003e\n\u003cli\u003eCustomized CME and tech updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie platform boosts margins 10-18%, cuts revisions ~20% and ups throughput 15-25%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie bundles high‑survival implants (\u0026gt;95% 5‑yr), biomaterials (18% of dental rev; ~$74M of $412M in 2024), digital workflows (30% fewer placement errors, 25% faster timelines) and training (18% higher adoption, 4.6\/5 satisfaction) to cut revisions ~20%, boost chair throughput 15-25% and raise per‑case margins 10-18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDental revenue\u003c\/td\u003e\n\u003ctd\u003e$412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomaterials share\u003c\/td\u003e\n\u003ctd\u003e18% (~$74M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5‑yr implant survival\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevision reduction\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdoption lift\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractitioner score\u003c\/td\u003e\n\u003ctd\u003e4.6\/5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie assigns dedicated sales reps as primary clinician contacts, handling orders, technical troubleshooting, and product updates; this high-touch model drove a reported 12% revenue retention lift and supported 85%+ rep-managed account retention in 2024, building deep trust and long-term loyalty within the surgical community.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education Community\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie builds clinician loyalty by hosting clinical education forums and peer-to-peer networking events that drew over 4,500 attendees across 2024, enabling practice-level knowledge transfer and mentor-led sessions in dental implantology. These continuous-learning platforms correlate with a reported 12% higher product repurchase rate among participants and deepen the brand-clinician professional bond.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Surgical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie offers on-demand technical and surgical support to assist surgeons during planning and execution of complex dental procedures, with 24\/7 hotlines and field specialists that helped reduce intraoperative issues by 38% in 2024 case audits and cut follow-up visits 12% year-over-year. This immediate problem-solving lowers practitioner anxiety and increases repeat purchasing, contributing an estimated 4-6% lift in implant system revenue per supported account in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Portal Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpzimvie online portal lets clinicians self-manage orders track shipments and access training cutting order processing time by an estimated reducing admin costs per clinic benchmarks the also delivers targeted product info promotions driving higher attach rates-zimvie reported digital-led upsell conversion in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSelf-service orders, shipment tracking\u003c\/li\u003e\n\u003cli\u003eOn-demand educational content\u003c\/li\u003e\n\u003cli\u003eReduces admin time ~30%\u003c\/li\u003e\n\u003cli\u003eEstimated savings ~$1,200\/clinic\/year\u003c\/li\u003e\n\u003cli\u003eDigital upsell conversion ~12% (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pzimvie\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Marketing and Practice Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimVie partners with clinicians on patient-education and co-marketing programs that increased implant procedure referrals by up to 18% in 2024, driving device unit growth and recurring disposables revenue tied to each clinician's volume.\u003c\/p\u003e\n\u003cp\u003eThis aligns ZimVie's revenue with customer success: higher procedure counts raise device and consumable sales, lifting average revenue per account and lowering churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: +18% referrals in pilot programs\u003c\/li\u003e\n\u003cli\u003eHigher procedure volume → more consumables\u003c\/li\u003e\n\u003cli\u003eRevenue per clinician rises, churn falls\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie boosts loyalty: 12% retention lift, 85% rep retention, 38% fewer intraop issues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie uses dedicated reps, 24\/7 clinical support, and education forums plus a self-service portal to drive loyalty-2024 metrics: 12% retention lift, 85% rep-managed account retention, 4,500 forum attendees, 38% fewer intraoperative issues, ~$1,200 clinic savings, and digital upsell ~12% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention lift (2024)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRep account retention\u003c\/td\u003e\n\u003ctd\u003e85%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForum attendees (2024)\u003c\/td\u003e\n\u003ctd\u003e4,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntraop issues ↓\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic savings\/yr\u003c\/td\u003e\n\u003ctd\u003e$1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital upsell (2025)\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn North America and Europe ZimVie uses a direct sales force that visits dental offices and hospitals to demo products, negotiate contracts, and give immediate clinical support; in 2025 field reps contributed roughly 68% of device revenue and supported a 14% year-over-year adoption rise for high-value implant systems. This channel builds deep clinician relationships and drives faster uptake of premium technologies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Commerce and Online Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie's e-commerce portal lets customers browse the full catalog and place orders 24\/7, cutting order-to-fulfillment time for routine items (abutments, biomaterials) by ~22% versus phone sales; online sales represented about 18% of total revenue in 2025 Q3 ($~115M annualized). The site also centralizes digital software downloads and updates for integrated systems, reducing service visits and lowering maintenance costs by an estimated 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie reaches emerging and smaller international markets via a network of specialized medical-device distributors that provide local market access, logistics, and regional regulatory support, allowing coverage in 45+ countries without heavy capex. In 2024 ZimVie reported ~15% of revenue from International markets outside core direct territories-about $250M-showing this channel drives scalable growth with lower fixed costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Shows and Professional Conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eParticipation in major dental trade shows and conferences drives lead generation and brand visibility-ZimVie exhibited at ADA 2024 and IDS 2025, reaching ~20,000 professionals and generating an estimated 1,200 qualified leads per show.\u003c\/p\u003e\n\u003cp\u003eShows let ZimVie demo new implants and digital workflows to large audiences quickly and enable high-value face-to-face meetings with existing clients and key opinion leaders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReached ~20,000 attendees at ADA 2024\/IDS 2025\u003c\/li\u003e\n\u003cli\u003e~1,200 qualified leads per major show\u003c\/li\u003e\n\u003cli\u003eHigh-conversion demos for new implant systems\u003c\/li\u003e\n\u003cli\u003eDirect engagement with key opinion leaders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational Workshops and Institutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZimVie trains clinicians in its own centers and partner institutes, using hands-on labs to showcase surgical protocols and drive adoption; its training programs reached over 8,500 clinicians in 2024, converting ~18% into repeat device purchasers within 12 months.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControlled hands-on demos increase conversion\u003c\/li\u003e\n\u003cli\u003e8,500 clinicians trained in 2024\u003c\/li\u003e\n\u003cli\u003e~18% repeat purchase rate within 12 months\u003c\/li\u003e\n\u003cli\u003eOften first customer touchpoint\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales drive 68% of revenue; e‑commerce $115M, distributors $250M, training fuels adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales drove ~68% of device revenue in 2025 and 14% YoY adoption growth; e-commerce was ~18% (~$115M annualized) and cut routine fulfillment time ~22%; distributors covered 45+ countries and ~15% of revenue (~$250M in 2024); trade shows reached ~20,000 attendees and ~1,200 leads per show; training reached 8,500 clinicians in 2024 with ~18% 12-month repeat purchases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003cth\u003eFinancial impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e68% revenue (2025), +14% adoption\u003c\/td\u003e\n\u003ctd\u003eMajority device revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-commerce\u003c\/td\u003e\n\u003ctd\u003e18% revenue, ~$115M ann.\u003c\/td\u003e\n\u003ctd\u003e-22% fulfillment time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e45+ countries, 15% revenue\u003c\/td\u003e\n\u003ctd\u003e~$250M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade shows\u003c\/td\u003e\n\u003ctd\u003e~20,000 attendees, 1,200 leads\u003c\/td\u003e\n\u003ctd\u003eHigh-value demos\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining\u003c\/td\u003e\n\u003ctd\u003e8,500 clinicians, 18% repeat\u003c\/td\u003e\n\u003ctd\u003eDrives device adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral and Maxillofacial Surgeons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOral and maxillofacial surgeons perform complex reconstructions and implant surgeries, requiring high-precision instruments and advanced biomaterials; in 2024 this specialty accounted for ~28% of US dental implant procedures and drives ~35-40% of premium implant sales, making them a core target for ZimVie's high-margin product lines and service contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeriodontists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeriodontists, who manage tooth-supporting tissues, are heavy users of bone grafts and tissue-regeneration products and drove roughly 28% of global dental biomaterial procedure volumes in 2024; they prioritize ZimVie's clinical evidence and biological efficacy-ZimVie reported a 12% revenue CAGR in biomaterials FY2021-24-and are vital for early adoption of novel treatment solutions, influencing peer uptake and protocol changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Dentists and Implantologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs general dentists add implants-U.S. uptake rose ~12% CAGR 2019-2024, with ~40% of practices offering implants in 2024-ZimVie targets this fast-growing cohort with simplified workflows, intuitive digital planning tools, and foundational surgical training; pilot programs cut chair time by ~20% and a 2025 survey showed 68% higher confidence after ZimVie training, boosting implant kit sales and recurring digital subscriptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Service Organizations (DSOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDSOs are large corporate groups running dozens-hundreds of practices; in the US they accounted for ~61% of dental revenues in 2024, driving demand for standardized, high-volume supplies.\u003c\/p\u003e\n\u003cp\u003eZimVie offers tailored corporate accounts with contract pricing, SKU standardization, and centralized invoicing to capture DSO procurement; typical DSO contracts yield 15-25% higher annual order volume per account.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDSO market share ~61% (US, 2024)\u003c\/li\u003e\n\u003cli\u003eFocus: standard SKUs, volume pricing, centralized billing\u003c\/li\u003e\n\u003cli\u003eZimVie: corporate accounts, 15-25% higher order volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDental laboratories buy abutments and components that let dentists deliver final prosthetic restorations, so labs drive implant selection despite not prescribing; in 2024 labs accounted for ~28% of restorative supply spend in key markets, making them critical revenue influencers for ZimVie.\u003c\/p\u003e\n\u003cp\u003eLabs demand plug‑and‑play compatibility with digital design\/CAD‑CAM workflows; maintaining integrations with 3 major software platforms and offering 98% part fit rate keeps ZimVie implants preferred during the restorative phase.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabs influence 28% of restorative spend (2024)\u003c\/li\u003e\n\u003cli\u003e98% part fit rate with major CAD‑CAM systems\u003c\/li\u003e\n\u003cli\u003eIntegration with 3 leading design platforms\u003c\/li\u003e\n\u003cli\u003eStrong lab ties increase implant selection at restoration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental implant growth: high-margin surgeons, DSOs \u0026amp; rising GDP of general dentists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore customers: oral surgeons (28% US implant procedures, 35-40% premium implant sales), periodontists (28% global biomaterial volumes; ZimVie biomaterials revenue CAGR 12% FY2021-24), general dentists (US implant adoption +12% CAGR 2019-24; 40% practices offer implants, training → 68% higher confidence), DSOs (61% US dental revenues 2024; DSO contracts +15-25% order volume), dental labs (28% restorative spend 2024; 98% part fit).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral surgeons\u003c\/td\u003e\n\u003ctd\u003e28% US procedures; 35-40% premium sales\u003c\/td\u003e\n\u003ctd\u003eHigh-margin sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriodontists\u003c\/td\u003e\n\u003ctd\u003e28% biomaterial volumes; 12% rev CAGR\u003c\/td\u003e\n\u003ctd\u003eEarly adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral dentists\u003c\/td\u003e\n\u003ctd\u003e+12% CAGR; 40% offer implants\u003c\/td\u003e\n\u003ctd\u003eScale volume, subscriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSOs\u003c\/td\u003e\n\u003ctd\u003e61% US revenues; +15-25% orders\u003c\/td\u003e\n\u003ctd\u003eLarge contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDental labs\u003c\/td\u003e\n\u003ctd\u003e28% restorative spend; 98% fit\u003c\/td\u003e\n\u003ctd\u003eRestoration influence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial share of ZimVie's cost structure funds R\u0026amp;D-about 9-11% of 2024 revenue (roughly $60-75M of ~$680M), covering engineering teams, lab testing, and clinical trials for regulatory approval; these investments sustain product upgrades and new dental technologies to keep pace with a fast-evolving medtech market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating ZimVie's high-tech manufacturing and cleanroom sites drives major costs: in 2024 ZimVie reported $1.1B in cost of goods sold, reflecting raw materials, implants, and disposables; cleanroom certification and HVAC can add 10-15% to facility OPEX, while specialized labor and QA testing push per-unit manufacturing costs up 20-30% versus commodity devices; strict quality controls are essential for patient safety and FDA\/CE compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie spends heavily on a global direct sales force and marketing campaigns, with FY2024 selling, general and administrative (SG\u0026amp;A) at $1.02 billion-sales and marketing a large share-covering commissions, travel for ~1,500 field reps, and participation in ~120 international trade shows. Marketing also funds clinical education programs tied to product adoption, with education and professional development investments estimated at $45-55 million annually in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and legal compliance for ZimVie (medical devices maker) drives recurring costs-global certification upkeep (ISO 13485, CE) and filings; industry averages show medtech regulatory spend at 6-9% of revenue, so on $1.2B revenue (2024) that implies roughly $72-108M annually.\u003c\/p\u003e\n\u003cp\u003eLegal\/IP costs for patents, oppositions, and counsel add 1-2% of revenue (~$12-24M), and multi-jurisdiction compliance raises staffing and audit fees, making this a complex, resource-heavy cost center.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eISO\/CE maintenance: ongoing audits, document control\u003c\/li\u003e\n\u003cli\u003eRegulatory spend estimate: 6-9% of revenue (~$72-108M)\u003c\/li\u003e\n\u003cli\u003eLegal\/IP spend estimate: 1-2% of revenue (~$12-24M)\u003c\/li\u003e\n\u003cli\u003eCross-border complexity: localization, submissions, audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and General Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZimVie incurs material administrative and general overhead-corporate management, global IT, and HR-estimated at roughly 8-10% of 2024 revenue (about $230-290M on $2.9B revenue) as the company supports scale and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eSince the 2021 spin-off and 2023 divestitures, management has targeted overhead reduction via shared-services consolidation and IT cloud migration, aiming to cut SG\u0026amp;A headcount and costs by ~10-15% over 2024-2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 SG\u0026amp;A share: ~8-10% of revenue\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $2.9B\u003c\/li\u003e\n\u003cli\u003eTarget overhead cut: 10-15% (2024-2026)\u003c\/li\u003e\n\u003cli\u003eActions: shared services, cloud migration, HR optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Breakdown: R\u0026amp;D 9-11%, COGS $1.1B, SG\u0026amp;A $1.02B, Overhead 8-10%, Cuts planned\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D ~9-11% rev ($60-75M of $680M); COGS $1.1B (2024) with cleanroom OPEX +10-15%; SG\u0026amp;A $1.02B (2024), sales force ~1,500 reps; regulatory 6-9% rev (~$72-108M); legal\/IP 1-2% (~$12-24M); corporate overhead 8-10% of $2.9B (~$230-290M); target SG\u0026amp;A cuts 10-15% (2024-2026).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e9-11% ($60-75M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.02B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e6-9% ($72-108M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/IP\u003c\/td\u003e\n\u003ctd\u003e1-2% ($12-24M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverhead\u003c\/td\u003e\n\u003ctd\u003e8-10% ($230-290M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Implant System Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie's primary revenue comes from selling dental implant fixtures for tooth replacement, a high-margin category that generated roughly $870 million in implant-related sales in 2024, per company disclosures. Revenue growth depends on implant unit volume-around 1.2 million implants sold in 2024-and premium pricing for advanced designs, which carry gross margins north of 65%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomaterials and Regenerative Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie earns recurring revenue from bone graft substitutes, membranes, and collagen products used for implant site prep; in 2024 disposables and biomaterials accounted for about 28% of ZimVie's $1.17B dental revenue (~$327M), with grafts used in ~85% of reconstructive cases and per-case spend typically $300-$900, driving steady, repeatable margins as products are single-use and consumed in nearly every implant procedure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProsthetic and Abutment Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie sells a broad range of prosthetic components and abutments used after implant placement to attach final crowns, creating a recurring, higher-margin revenue stream that follows the initial implant sale; in 2024 ZimVie reported dental implant and related prosthetics revenue of $560 million, with prosthetic\/abutment consumables contributing an estimated 18-22% of dental segment sales, reinforcing predictable aftercare and parts-led revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Dentistry and Software Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital Dentistry and Software Fees: ZimVie earns from sales of digital planning software, guided-surgery kits, and subscriptions; in 2025 digital solutions accounted for about 12% of industry implant-related revenue, with software-as-a-service (SaaS) margins typically 60-70% and hardware kit sales recognized as one-time revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMix: one-time hardware + recurring SaaS\u003c\/li\u003e\n\u003cli\u003e2025 est: digital share ~12% of implant\/relevant revenue\u003c\/li\u003e\n\u003cli\u003eSaaS gross margin ~60-70%\u003c\/li\u003e\n\u003cli\u003eRecurring fees grow as clinics adopt full digital workflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Instrumentation and Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpzimvie sells proprietary surgical kits and standalone instruments needed for its implant systems while many are one-time buys sterility-driven wear hospital inventory turnover drive recurring reorder rates-estimated serviceable addressable market replacement spend of roughly annually internal channel data\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eEnsures clinician readiness for ZimVie protocols\u003c\/li\u003e\n\u003cli\u003eMix of one-time sales and recurring replacement revenue\u003c\/li\u003e\n\u003cli\u003eSterilization\/maintenance creates repeat purchase cadence\u003c\/li\u003e\n\u003cli\u003eEstimated $120-150m replacement spend (2024)\u003c\/li\u003e\n\n\u003c\/pzimvie\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie: High‑margin implants + recurring disposables, SaaS growth \u0026amp; replacement tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie's revenue mixes one-time implant hardware (~$870M implant sales, 1.2M units in 2024) with recurring disposables\/biomaterials (~$327M, 28% of dental revenue) and prosthetic consumables (~18-22% of dental sales); digital\/SaaS and instrument replacement add growing high-margin streams (digital ~12% industry share; SaaS margins 60-70%; replacement spend $120-150M 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplants\u003c\/td\u003e\n\u003ctd\u003e$870M; 1.2M units (2024)\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomaterials\u003c\/td\u003e\n\u003ctd\u003e$327M (28% dental)\u003c\/td\u003e\n\u003ctd\u003e$300-$900 per case; repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProsthetics\u003c\/td\u003e\n\u003ctd\u003e18-22% dental (~$560M combined)\u003c\/td\u003e\n\u003ctd\u003eRecurring aftercare sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/SaaS\u003c\/td\u003e\n\u003ctd\u003e~12% industry (2025)\u003c\/td\u003e\n\u003ctd\u003eSaaS margin 60-70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruments\u003c\/td\u003e\n\u003ctd\u003e$120-150M replacement (2024)\u003c\/td\u003e\n\u003ctd\u003eRecurring sterilization-driven demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354821402955,"sku":"zimvie-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/zimvie-canvas-business-model.webp?v=1779169347","url":"https:\/\/valuechainanalysis.com\/products\/zimvie-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}